Summary
Bivalirudin failed to show a superior “net clinical benefit” compared with unfractionated heparin (UFH) in patients undergoing percutaneous coronary intervention in the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment 3 [ISAR-REACT 3] trial. However, bivalirudin reduced the rate of major and minor bleeding events in this patient population.
- interventional techniques & devices clinical trials
- thrombotic disorders
- © 2008 MD Conference Express
Tools
Bivalirudin Not Superior to Unfractionated Heparin in Patients Receiving 600 mg Clopidogrel Prior to PCI
Permalink:
Table of contents
Cited By...
- No citing articles found.